Research programme: autoimmune disease therapeutics - BioMed X/Janssen Research & Development
Latest Information Update: 28 Nov 2021
At a glance
- Originator BioMed X; Janssen Research & Development
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Autoimmune-disorders in Germany
- 28 Nov 2021 No recent reports of development identified for research development in Autoimmune-disorders in USA
- 09 Nov 2020 BioMed X expands its research and development collaboration with Janssen for Autoimmune disorders